Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.

ABSTRACT:

Background

Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD).

Objective

To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD.

Design

Multicenter, randomized, parallel-group, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT02168842).

Setting

57 Parkinson Study Group sites in North America.

Participants

Patients with early-stage PD (duration <3 years) who were not taking dopaminergic medications at enrollment.

Intervention

5 mg of immediate-release isradipine twice daily or placebo for 36 months.

Measurements

The primary outcome was change in the Unified Parkinson's Disease Rating Scale

SUBMITTER: Parkinson Study Group STEADY-PD III Investigators 

PROVIDER: S-EPMC7465126 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature